Jesse G. Zalatan

This paper introduces cSAGE, a conjugation-based genome engineering platform that enables site-specific integration in transformation-resistant bacteria, demonstrating its utility in bioproduction pathway prototyping.

The paper introduces CRISPRi-assisted E. coli strains to improve cloning success for burdensome genetic constructs by reducing metabolic burden during cloning.

The paper introduces CIRI, a CRISPR-based platform for programmable cell fate conversion in hiPSCs, using single-cell genomics to identify regulatory factors for myogenic differentiation.

The paper introduces mapSPLiT, a pooled CRISPRa/i screening platform for bacteria, linking perturbations to single-cell transcriptomes and expanding regulatory networks in E. coli and P. putida.

This study systematically maps bacterial CRISPRa design rules and finds no synergistic activation, highlighting mechanistic differences from eukaryotic systems.

This paper computationally designs multi-component protein filaments that assemble into ordered fibers, validated by cryoEM, and shows regulation via phosphorylation.

The paper uses ProteinMPNN to stabilize Fe(II)/KG enzymes, enabling more effective directed evolution of new catalytic functions.

The paper designs guide RNA structures for CRISPRa to optimize multi-gene expression in bacterial metabolic pathways, achieving higher product titers and identifying pathway bottlenecks.

The paper develops CRISPR-Cas tools to independently control transcription and translation in E. coli, showing reduced polar effects with dCas13 and enabling multiplexed gene regulation for biosynthesis.

This study evaluates PAM-flexible dCas9 variants for bacterial CRISPR activation and repression, finding trade-offs between PAM flexibility and repression efficiency.

This study shows that CRISPR-Cas-mediated tethering recruits the yeast HMR locus to the nuclear periphery but does not silence gene expression, unlike a Gal4-mediated system.

This study identifies strict target site requirements for effective CRISPRa in bacteria and demonstrates a dCas9 variant with expanded PAM specificity to overcome these limitations.